Lipo-C Fat Blaster vs AOD-9604
Lipo-C is a compounded injectable mixture whose typical constituents are methionine, inositol, choline, L-carnitine and vitamin B12, and the published literature addresses those substances individually rather than as a combined injection. AOD-9604 is a single synthetic hexadecapeptide corresponding to the C-terminal lipolytic domain of human growth hormone, written as Tyr-hGH 177-191 or hGH fragment 176-191. The two are compared because both are sold as injectable aids to fat loss, but one is a nutrient mixture with a component-level evidence base built mostly from oral supplementation trials, and the other is a peptide whose primary pharmacology was published between 1993 and 2001 and whose only human report in the indexed literature is a pooled safety analysis. No study has tested them against each other. One obesity pharmacotherapy review engages both the peptide and one of the mixture's components, and it is the sole publication located that does so.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has compared a lipotropic injection with AOD-9604, and searches of PubMed and Europe PMC pairing the peptide with methionine, inositol, choline, L-carnitine, vitamin B12 and lipotropic terms returned no experiment containing both. The single publication that engages the peptide alongside one of the mixture's components is a 2010 review of antiobesity pharmacotherapy. It described AOD-9604 as a modified fragment of growth hormone amino acids 177-191 developed to reproduce the lipolytic effects of growth hormone without its growth effects, recounted a twelve-week randomised clinical trial in which recipients lost more weight on average than placebo recipients, and recorded that the compound subsequently failed to produce significant weight loss in a 24-week trial of 536 subjects and was later licensed for a transdermal cosmeceutical application. In a separate section on non-prescription products the same review listed L-carnitine among dietary supplements promoted to enhance fat oxidation, and stated that none of those supplements had been proven in clinical trials to induce significant weight loss and that no evidence existed for their long-term safety. The two are described in different sections and were never compared.
The publication that covers both
- 01Review2010
Central and peripheral molecular targets for antiobesity pharmacotherapy
Valentino MA, Lin JE, Waldman SA · Clin Pharmacol Ther · narrative review of central and peripheral molecular targets for antiobesity pharmacotherapy, covering approved drugs, investigational agents and non-prescription dietary supplements
The review described AOD-9604 as a modified fragment of growth hormone amino acids 177-191 intended to mimic the lipolytic effects of growth hormone without growth effects, reported a twelve-week randomised clinical trial in which treated subjects lost more weight on average than those given placebo, and recorded that the compound failed to induce significant weight loss in a 24-week trial of 536 subjects, after which it was licensed for a transdermal cosmeceutical application. Separately, L-carnitine appeared among dietary supplements promoted to enhance fat oxidation, of which the review stated that none had been proven in clinical trials to induce significant weight loss and that no evidence existed for their long-term safety.
Side by side.
| Lipo-C Fat Blaster | AOD-9604 | |
|---|---|---|
| Evidence maturity | Clinical | Early clinical |
| Studies cited here | 15 | 17 |
| Published 2023 or later | 11 | 4 |
| Newest paper | 2026 | 2026 |
| What the product is | A compounded injectable mixture of nutrients, typically methionine, inositol, choline, L-carnitine and vitamin B12, prepared by compounding rather than manufactured to a single approved specification. | A single synthetic hexadecapeptide corresponding to the C-terminal lipolytic domain of human growth hormone, with an added N-terminal tyrosine distinguishing the synthesised analogue. |
| Mechanism as described in the literature | Described at component level: choline availability and hepatic fat accumulation, L-carnitine and mitochondrial fatty acid transport, inositol and insulin signalling, methionine and one-carbon metabolism, and vitamin B12 status in metabolic disease. No mechanism has been described for the mixture as a whole. | Reduction of lipogenic activity and stimulation of lipolysis and fat oxidation in adipose tissue, reported to occur without measurable interaction with the growth hormone receptor and without elevation of IGF-1. |
| Size of the evidence base | Fifteen studies in this library, all at component level: nine systematic reviews or meta-analyses, five human clinical studies and one narrative review. None studied the combined injectable preparation. | Seventeen studies: seven animal in vivo, five in vitro, four reviews and one human pooled safety analysis. |
| Human data | Extensive but component-level. Pooled analyses include 37 randomised L-carnitine trials in 2,292 participants, an umbrella analysis of eight prior meta-analyses covering 16,352 participants, inositol meta-analyses in polycystic ovary syndrome and gestational diabetes prevention, and controlled choline depletion-repletion and methionine-restriction studies. | One pooled safety and tolerability analysis of six randomised, double-blind, placebo-controlled trials, published in 2013. No efficacy trial has appeared as a standalone peer-reviewed report, so body-composition outcomes have not been independently published in an indexed journal. |
| Route studied against route sold | Nearly all the underlying evidence comes from oral supplementation or dietary-intake studies; the injected multi-ingredient preparation has no published pharmacokinetics, and a 2025 meta-analysis of vitamin B12 compared oral, sublingual and intramuscular routes without addressing the mixture. | The published human work used intravenous and oral administration, and the non-clinical package published in 2014 supported a food-ingredient position. Injectable use in humans is not addressed in the peer-reviewed record. |
| Best-characterised finding | A 2020 systematic review and meta-analysis of 37 randomised trials of oral L-carnitine reported pooled reductions in body weight, BMI and fat mass, with no significant pooled effect on waist circumference or body fat percentage. | Reduced lipogenesis and increased fat oxidation in rodent obesity models in work published between 1993 and 2001, including chronic dosing studies in obese mice and Zucker fatty rats. |
| Recency of primary research | Active at component level, with systematic reviews and meta-analyses of L-carnitine, inositol, vitamin B12 and choline published in 2025 and 2026, none of which examined the mixture. | Primary pharmacology ended around 2001. Later literature is dominated by anti-doping analytical chemistry, an identification of the peptide in seized preparations, a rabbit intra-articular osteoarthritis study and narrative reviews of peptides in orthopaedics and sports medicine. |
| Basis of most marketing claims | Extrapolation from oral single-component trials in defined clinical populations to an injected multi-ingredient product whose additive or interactive effects have never been measured. | Extrapolation from rodent lipolysis data and a human safety analysis to fat-loss outcomes that no published efficacy trial has demonstrated. |
And what it does not.
Neither product has published evidence for what it is sold to do, and no study has weighed one against the other. The Lipo-C literature is real but belongs to its individual constituents, generated mostly by oral supplementation in defined clinical populations, and the pooled effects reported for the most-studied component, L-carnitine, are small and inconsistent across endpoints. The combined injectable preparation has never been evaluated in a controlled trial, and its pharmacokinetics and interactive effects are unpublished. AOD-9604 has a coherent rodent pharmacology from the 1990s and a pooled human safety analysis, but no standalone peer-reviewed efficacy trial, and the one review that engages it records a failure to produce significant weight loss in a 24-week study of 536 subjects. Read together, the two evidence bases describe a nutrient mixture whose parts have been tested by a route other than the one sold, and a peptide whose human efficacy record was never published in full.
Common questions.
- Has any study compared a lipotropic injection with a growth hormone fragment?
No. Searches of PubMed and Europe PMC pairing AOD-9604 and hGH fragment 176-191 with methionine, inositol, choline, L-carnitine, vitamin B12 and lipotropic injection terms returned no experiment containing both. The only publication that engages the peptide alongside one of the mixture's components is a 2010 antiobesity pharmacotherapy review, which discusses them in separate sections. No comparative efficacy, safety or pharmacokinetic data exist for the pair.
- What did the 2010 obesity pharmacotherapy review say about each?
It described AOD-9604 as a growth hormone fragment designed to reproduce lipolytic effects without growth effects, noted a twelve-week randomised trial in which treated subjects lost more weight on average than placebo recipients, and recorded a subsequent failure to produce significant weight loss in a 24-week trial of 536 subjects. Elsewhere it listed L-carnitine among supplements promoted to enhance fat oxidation, none of which, it stated, had been proven in trials to induce significant weight loss.
- Do the L-carnitine meta-analyses describe injected carnitine?
No. The pooled analyses that underpin the component-level evidence, including a 2020 systematic review of 37 randomised trials and a 2025 umbrella analysis of eight prior meta-analyses, drew almost entirely on oral supplementation across widely varying doses and durations. Their reported reductions in body weight, BMI and fat mass therefore describe oral administration in defined populations, and no published study has measured the same endpoints for carnitine delivered as part of a compounded injectable mixture.
- Is there a published efficacy trial for either product as sold?
For neither. The combined injectable lipotropic formulation has not been evaluated in any controlled trial, and no published study has assessed its pharmacokinetics, additive effects or clinical endpoints. For AOD-9604 the human literature consists of a pooled safety and tolerability analysis of six randomised placebo-controlled trials; no efficacy trial has appeared as a standalone peer-reviewed report, so the body-composition results have not been independently published.
- Why does component evidence not carry over to the mixture?
Because dose, route, population and duration all differ from the marketed preparation. The underlying trials examined single nutrients taken orally, often in people selected for a specific condition such as polycystic ovary syndrome, non-alcoholic fatty liver disease or metabolic syndrome. A compounded injection delivers several substances together by a different route, and its absorption, interactions and combined effects have never been measured, so an outcome observed for one component in one setting cannot be attributed to the mixture.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.